Companies: 10,795·Total market cap: $144.5T
Bonus BioGroup Ltd.

Bonus BioGroup Ltd.

BBIXFOTCHealthcare● Active
$0.13
+$0.00(+0.00%)
Market Cap$151830290
P/E Ratio
52W High$0.15
52W Low$0.0001

Bonus BioGroup Ltd. (BBIXF) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

bbixf · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Bonus BioGroup Ltd. (BBIXF) measures how much investors pay for each dollar of the company's trailing earnings. BBIXF's current PE ratio of N/A is calculated by dividing its stock price of $0.13 by its TTM earnings per share of -$0.03.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
EPS (TTM)
-$0.03
TTM · diluted EPS
PEG Ratio
-0.29
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bonus BioGroup Ltd. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2012 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Bonus BioGroup Ltd.
Bonus BioGroup Ltd.You
BBIXF
$152MN/A-$0.03
Cell Source, Inc.
Cell Source, Inc.
CLCS
$37MN/A-$0.11
Cordlife Group Limited
Cordlife Group Limited
CLIFF
$23MN/A-$0.05
Celyad Oncology S.A.
Celyad Oncology S.A.
CLYYF
$11M6.58x$0.02
EvoNext Holdings S.A.
EvoNext Holdings S.A.
ELVAF
$8MN/A-$0.09
Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc.
FNCH
$12MN/A-$8.64
ImpediMed Limited
ImpediMed Limited
IPDQF
$11MN/A-$0.01

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 14 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.04
2024-12-31
FY2024
$-0.02
2023-12-31
FY2023
$-0.02
2022-12-31
FY2022
$-0.03
2021-12-31
FY2021
$-0.08
2020-12-31
FY2020
$-0.02
2019-12-31
FY2019
$-0.03
2018-12-31
FY2018
$-0.02
2017-12-31
FY2017
$-0.02
2016-12-31
FY2016
$-0.07

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Bonus BioGroup Ltd. (BBIXF) measures how much investors pay for each dollar of the company's trailing earnings. BBIXF's current PE ratio of N/A is calculated by dividing its stock price of $0.13 by its TTM earnings per share of -$0.03.

PE Ratio = Stock Price ÷ EPS (TTM)
= $0.13 ÷ -$0.03 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

BBIXF pe ratio · 6 questions

BBIXF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.13 and TTM EPS of -$0.03. Data sourced from Financial Modeling Prep via BBIXF's SEC 10-K and 10-Q filings.

BBIXF PE ratioWhat is BBIXF PE ratioCurrent PE ratio of BBIXFBBIXF PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bonus BioGroup Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09